Healthcare Business: The impeccable ayur chemistry
When the chronic illnesses hit half the American population, the rate in India is far less at 20 per cent. This is mainly because of allopathic medicines, which more Americans depend on, are ineffective in reversing the disorder, while Ayurvedic medicines have proved their effectiveness. In India the number of people depending on Ayurvedic medicines has always been higher. That will grow further giving a boost to the Ayurvedic medical business.
Doctors have begun to prescribe medicines in English. The number of branded prescription category is increasing. Private hospitals are coming up. There are entrepreneurs, who are willing to risk their money on building large format hospitals, which will one day play a major role in boosting India’s medical tourism. The world is increasingly looking at India’s invaluable traditional health system, which offers curable solution to many incurable illness and quality life. According to the World Health Organization (WHO), roughly 70–80% of the world populations depend on nonconventional medicines, mainly of herbal sources for their health care. Indian Ayurveda, obviously stands on the top of this.
But it is yet not a big business as an organized sector, though it has the limitless potential to be so. The world is changing fast as the densely populated third world economy is changing, while the developed western world is crippling on rising chronic and terminal illness. They have their soaring medical business, simultaneously making itself increasingly expensive. The bad chemistry of modern drugs is leaving on them a life that is not sustainably healthy. The Illness is suppressed with heavy drug doses but patients are not free of sickness as their body cannot sustain the inducement. They wrongly see traditional medicine a bad science, carrying with them a slavery of research report the bribed propaganda.
People around the world usually buy what western laboratories concluded in their research, especially in the third world. Once they used to boast about spending high on research and development (R&D) as well as on drug delivery processes. That has made the allopath streams steal the world of medical science. Still billions are spent on medical research, innovation in treatments, diagnostic systems, drug delivery etc. When billions are spent, which can prudentially be called investments, businesses of trillions come to their focus. Today that is what the western world is paying for. Still there are many areas where in research work couldn’t tackle challenges of many chronic and terminal illnesses, so is the drug development works.
Roughly half of 327.30 million total American population suffers chronic diseases like diabetes, heart disease, stroke, cancer and obstructive pulmonary disease, reports show. If the estimates of National Association of Chronic Disease Directors (NACDD) of the US are right, an average American spends close to $ 1100 a year for treatment of chronic disease. We can compare the American size of chronic disease with what India has – that is 20 per cent. With 20 per cent Indians suffering chronic disease, the number of patients in India is still less than the US numbers, despite the fact the US has only a quarter of India’s population.
The chronic diseases and terminal illnesses have no solution in the ubiquitous allopathic medical science. That is the reason the number of chronic and terminal illness victims is high in the US and the same is much lower in India. India has less than half of what the US has at present. Most of the chronic illness especially the ones like rheumatoid arthritis is cured with the ayurvedic medicines, while the same is not curable with allopathic medicines. The allopathic can only give a momentary relief, that too through painkiller. The pain killer kills not only the pain but also the patients over a period. Doctors also usually advise patients to abstain from the habit of consuming painkillers. It is proved that arthritis is completely curable with Ayurvedic medicines, without giving any painkiller.
More Indian companies are now increasing their presence in the vast and most challenging US market. Last year, more than 300 Indian companies secured ANDA (Abbreviated New Drug Application) approvals from the USFDA (US Food and Drug Administration). Almost 30 per cent of the generic medicines consumed by Americans are made by Indian companies. On the other side, with increasing presence of Indian biotechnology companies in the US market working on verticals like bio-pharmaceuticals, bio-informatics, bio-industry and bio-agriculture, India is set to play bigger role in the US market. India’s ayurveda is the next big bet, especially in the context that the US requires effective medical intervention for saving its population from the chronic illnesses.
This stream of traditional health science deals with several classical formulations including arka, asavas, aristas, churna, taila, vati, gutika, bhasma etc, say some studies. “There are several lead molecules that have been developed from the Ayurvedic herbs, which have various significant therapeutic activities. Chemo-profiling of Ayurvedic drug is essential in order to assess the quality of products. It deals with bioactive compound quantification, spurious and allied drug determination, chromatographic fingerprinting, standardization, stability and quality consistency of Ayurvedic products,” some reports pointed out.
Roughly half of 327.30 million total American population suffers chronic diseases like diabetes, heart disease, stroke, cancer and obstructive pulmonary disease, reports show. We can compare the American size of chronic disease with what India has – that is 20 per cent. With 20 per cent Indians suffering chronic disease, the number of patients in India is still less than the US numbers, despite the fact the US has only a quarter of India’s population.
When billions are spent, which can prudentially be called investments, businesses of trillions come to their focus. Today that is what the western world is paying for. Still there are many areas where in research work couldn’t tackle challenges of many chronic and terminal illnesses, so is the drug development works.
There are several lead molecules that have been developed from the Ayurvedic herbs, which have various significant therapeutic activities.”
